Cytosorbents Corp. received European Union regulatory approval to expand the use of its CytoSorb blood purification technology to reduce high levels of bilirubin and myoglobin from the blood.
High levels of bilirubin, a bile pigment, are frequently associated with chronic liver disease and liver failure. Elevated myoglobin, a protein found in heart tissue and other muscles, is associated with accidents and traumatic injury.
The device is approved in the EU with distribution in 45 countries globally for extracorporeal cytokine adsorber that could otherwise cause massive inflammation, organ failure and death in common critical illnesses.
